173 related articles for article (PubMed ID: 24991188)
1. Absence of recognition of common melanocytic antigens by T cells isolated from the cerebrospinal fluid of a Vogt-Koyanagi-Harada patient.
Abad S; Wieërs G; Colau D; Wildmann C; Delair E; Dhote R; Brézin AP; Kawakami Y; Coulie PG; van der Bruggen P
Mol Vis; 2014; 20():956-69. PubMed ID: 24991188
[TBL] [Abstract][Full Text] [Related]
2. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens.
Sugita S; Takase H; Taguchi C; Imai Y; Kamoi K; Kawaguchi T; Sugamoto Y; Futagami Y; Itoh K; Mochizuki M
Invest Ophthalmol Vis Sci; 2006 Jun; 47(6):2547-54. PubMed ID: 16723469
[TBL] [Abstract][Full Text] [Related]
3. T-cell recognition and cytokine profile induced by melanocyte epitopes in patients with HLA-DRB1*0405-positive and -negative Vogt-Koyanagi-Harada uveitis.
Damico FM; Cunha-Neto E; Goldberg AC; Iwai LK; Marin ML; Hammer J; Kalil J; Yamamoto JH
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2465-71. PubMed ID: 15980237
[TBL] [Abstract][Full Text] [Related]
4. [Ocular infiltrating CD 4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens].
Sugita S
Nippon Ganka Gakkai Zasshi; 2008 Nov; 112(11):953-64. PubMed ID: 19069378
[TBL] [Abstract][Full Text] [Related]
5. Identification of autoreactive T cells in Vogt-Koyanagi-Harada disease.
Gocho K; Kondo I; Yamaki K
Invest Ophthalmol Vis Sci; 2001 Aug; 42(9):2004-9. PubMed ID: 11481264
[TBL] [Abstract][Full Text] [Related]
6. Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease.
Sugita S; Sagawa K; Mochizuki M; Shichijo S; Itoh K
Int Immunol; 1996 May; 8(5):799-803. PubMed ID: 8671669
[TBL] [Abstract][Full Text] [Related]
7. Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient.
Kobayashi H; Kokubo T; Takahashi M; Sato K; Miyokawa N; Kimura S; Kinouchi R; Katagiri M
Immunogenetics; 1998 Apr; 47(5):398-403. PubMed ID: 9510558
[TBL] [Abstract][Full Text] [Related]
8. Frequent immune response to a melanocyte specific protein KU-MEL-1 in patients with Vogt-Koyanagi-Harada disease.
Otani S; Sakurai T; Yamamoto K; Fujita T; Matsuzaki Y; Goto Y; Ando Y; Suzuki S; Usui M; Takeuchi M; Kawakami Y
Br J Ophthalmol; 2006 Jun; 90(6):773-7. PubMed ID: 16481377
[TBL] [Abstract][Full Text] [Related]
9. [Intraocular inflammation and homeostasis of the eye].
Mochizuki M
Nippon Ganka Gakkai Zasshi; 2009 Mar; 113(3):344-77; discussion 378. PubMed ID: 19348183
[TBL] [Abstract][Full Text] [Related]
10. A shared HLA-DRB1 epitope in the DR beta first domain is associated with Vogt-Koyanagi-Harada syndrome in Indian patients.
Tiercy JM; Rathinam SR; Gex-Fabry M; Baglivo E
Mol Vis; 2010 Mar; 16():353-8. PubMed ID: 20216938
[TBL] [Abstract][Full Text] [Related]
11. Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease.
Yamaki K; Gocho K; Hayakawa K; Kondo I; Sakuragi S
J Immunol; 2000 Dec; 165(12):7323-9. PubMed ID: 11120868
[TBL] [Abstract][Full Text] [Related]
12. T cell immune responses against melanoma and melanocytes in cancer and autoimmunity.
Kawakami Y; Suzuki Y; Shofuda T; Kiniwa Y; Inozume T; Dan K; Sakurai T; Fujita T
Pigment Cell Res; 2000; 13 Suppl 8():163-9. PubMed ID: 11041376
[TBL] [Abstract][Full Text] [Related]
13. Vogt-Koyanagi-Harada disease and vitiligo: where does the illness begin?
Prignano F; Betts CM; Lotti T
J Electron Microsc (Tokyo); 2008 Jan; 57(1):25-31. PubMed ID: 18174263
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical studies of Vogt-Koyanagi-Harada disease with sunset sky fundus.
Inomata H; Sakamoto T
Curr Eye Res; 1990; 9 Suppl():35-40. PubMed ID: 1974489
[TBL] [Abstract][Full Text] [Related]
15. Vitiligo in Vogt-Koyanagi-Harada disease: immunohistological analysis of inflammatory site.
Okada T; Sakamoto T; Ishibashi T; Inomata H
Graefes Arch Clin Exp Ophthalmol; 1996 Jun; 234(6):359-63. PubMed ID: 8738701
[TBL] [Abstract][Full Text] [Related]
16. Cross-reaction between tyrosinase peptides and cytomegalovirus antigen by T cells from patients with Vogt-Koyanagi-Harada disease.
Sugita S; Takase H; Kawaguchi T; Taguchi C; Mochizuki M
Int Ophthalmol; 2007; 27(2-3):87-95. PubMed ID: 17253112
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of proinflammatory cytokine by IL-25 in Vogt-Koyanagi-Harada syndrome.
Xu M; Wang C; Tian Y; Kijlstra A; Yang P
Ocul Immunol Inflamm; 2014 Aug; 22(4):294-9. PubMed ID: 24329541
[TBL] [Abstract][Full Text] [Related]
18. The role of interleukin-1 receptor-associated kinases in Vogt-Koyanagi-Harada disease.
Sun M; Yang P; Du L; Yang Y; Ye J
PLoS One; 2014; 9(4):e93214. PubMed ID: 24690905
[TBL] [Abstract][Full Text] [Related]
19. Vogt-Koyanagi-Harada syndrome--isolation of cloned T cells with specificity for melanocytes and melanoma cells.
McClellan KA; MacDonald M; Hersey P; Billson FA
Aust N Z J Ophthalmol; 1989 Nov; 17(4):347-52. PubMed ID: 2624724
[TBL] [Abstract][Full Text] [Related]
20. Class II major histocompatibility complex on melanocytes of Vogt-Koyanagi-Harada disease.
Sakamoto T; Murata T; Inomata H
Arch Ophthalmol; 1991 Sep; 109(9):1270-4. PubMed ID: 1929956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
